Last mentioned: Mar 5, 2026
Earnings Call Cycle
Management teams provide forward-looking guidance for the 2026 fiscal year.
Earnings Release
Company reports Q4 beat and issues bullish 2026 revenue guidance.
SEC Filings Peak
EOLS, QUIK, WEYS, and EML all file Q4 2025 financial results with the SEC.
QuickLogic Contract Win
Awarded $13M for SRH High Reliability FPGA technology development.
Evolysse Launch
Anticipated commercial rollout of the Evolysse dermal filler portfolio in the U.S.
Anticipated FDA Approval
Expected regulatory clearance for the first Evolysse filler products.
Commercial Launch
Planned U.S. launch of the Evolysse filler portfolio to aesthetic injectors.
Q4 Fiscal Close
Evolus concludes its strongest fiscal year to date with record Jeuveau sales.
Q4 Earnings
Company reports record revenue and market share for Jeuveau.
Filler Partnership
Evolus expands partnership with Symatese for the Evolysse dermal filler line.
The Q4 2025 earnings season for small-cap leaders reveals a resilient performance across the aesthetics, semiconductor, and industrial sectors. While Evolus continues to capture market share in the neurotoxin space, QuickLogic is leveraging significant new defense contracts to drive its high-reliability FPGA business.
Evolus, Inc. reported strong Q4 2025 results, driven by the continued market share expansion of its flagship neurotoxin, Jeuveau, and progress in its international rollout. The company remains on track to transform into a multi-product aesthetics platform with the anticipated 2026 launch of its Evolysse dermal filler line.
A cluster of Q4 2025 earnings reports from Evolus, Weyco Group, and The Eastern Company reveals a bifurcated retail landscape where performance beauty and specialized footwear are outperforming broader discretionary categories. While industrial hardware and semiconductor providers show steady infrastructure demand, consumer-facing entities are leveraging digital-first strategies to maintain margins.
Evolus reported record Q4 2025 financial results, triggering a significant stock rally following a revenue beat and robust 2026 guidance. The company's performance underscores the resilience of the medical aesthetics market and the growing adoption of its flagship neurotoxin, Jeuveau.